Kintara Therapeutics Q1 EPS $(1.83) Misses $(0.58) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kintara Therapeutics (NASDAQ:KTRA) reported a Q1 EPS loss of $(1.83), significantly missing the analyst consensus estimate of $(0.58) by 215.52%. However, this represents a 47.71% improvement from the $(3.50) per share loss reported in the same period last year.
November 13, 2023 | 10:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kintara Therapeutics reported a larger than expected Q1 loss per share of $(1.83), missing estimates by 215.52%, but improved from last year's $(3.50) loss.
The significant miss in earnings per share is likely to negatively impact investor sentiment and the stock price in the short term. Despite the year-over-year improvement, the extent of the miss may overshadow the positive aspect of reduced losses.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100